Loading patent…
AssigneeTargimmune Therapeutics AG
InventorsDerrick BROKA, David COLECCHIA, Lucia D'AMICO, Eric KITAS, Alexander LEVITZKI, Esteban POMBO-VILLAR, Alexei SHIR, Maya ZIGLER, Davor BAJIC, Anita JARZEBINSKA
Estimating the term…
The present invention relates to a kit-of-parts comprising and a composition comprising a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (PEG) moieties and one or more targeting moieties, and wherein each of said one or more targeting moieties is capable of binding to a cancer antigen; and at least one antibody, wherein said at least one antibody is capable of modulating an immune checkpoint protein. Further the invention relates to this composition or kit-of-parts for use in the treatment of cancer.
A kit-of-parts comprising
A composition comprising
The composition or the kit-of-parts according to any one of the preceding claims, wherein said immune checkpoint protein is selected from the group consisting of 4-1BB, 4-1BB ligand, PD-1, PD-L1, PD-L2 and CTLA-4, more preferably said immune checkpoint protein is selected from the group consisting of 4-1BB, 4-1BB ligand, PD-1, PD-L1, and PD-L2.
The composition or the kit-of-parts according to any one of the preceding claims, wherein said immune checkpoint protein is 4-1BB or PD-1.
The composition or the kit-of-parts of any one of the preceding claims, wherein said at least one antibody capable of modulating an immune checkpoint protein is a mixture of
The composition or the kit-of-parts according to any one of the preceding claims, wherein said PEI is covalently bound to one, two or three PEG moieties, preferably to one or three PEG moieties.
The composition or the kit-of-parts according to any one of the preceding claims, wherein said polyethyleneimine (PEI) is linear polyethyleneimine (LPEI).
The composition or the kit-of-parts according to any one of the preceding claims, wherein said dsRNA is polyinosinic-polycytidylic acid double stranded RNA (polyIC).
The composition or the kit-of-parts according to any one of the preceding claims, wherein said cancer antigen is EGFR, HER2 or PSMA, preferably said cancer antigen is EGFR.
The composition or the kit-of-parts according to any one of the preceding claims, wherein said one or more targeting moieties are selected from the group consisting of EGF, a HER2 affibody, a HER2 antibody, and a DUPA moiety (HOOC(CH2)2—CH(COOH)—NH—CO—NH—CH(COOH)—(CH2)2—CO—).
The composition or the kit-of-parts according to any one of the preceding claims, wherein said one or more targeting moieties is EGF, preferably human EGF.
The composition or the kit-of-parts according to any one of the preceding claims for use in the treatment of cancer in a mammal, preferably a human.
Dependencies are inferred from the claim text.